A Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Study to Evaluate the Treatment Effect of Pentosan Polysulfate Sodium Compared to Placebo in Participants With Knee Osteoarthritis Pain

The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.
Study details include:
* The study duration will be up to 64 weeks.
* The treatment duration will be 6 weeks.
* The visit frequency will be twice weekly during treatment.
* The visit/contact frequency will be every 4-6 weeks during the 52-week Follow-up period.
* Approximately 466 participants will be enrolled into this study.

开始日期2025-05-29

申办/合作机构

Paradigm Biopharmaceuticals Ltd.

CTRI/2024/01/061184

/ Not yet recruiting临床2期IIT

A randomized, open-label, parallel, Proof of concept, Investigator Initiated study to evaluate the efficacy and safety of Pentosan polysulfate sodium in adult patients with Diabetic Nephropathy - NIL

开始日期2024-01-11

申办/合作机构-

ACTRN12621000654853

/ Recruiting临床2期IIT

A Double-Blind, RandoMised, Placebo-Controlled Study to Assess theEfficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)compared to placebo in participants with symptomatic kneE osteoarthritis(OA) and dysLipidemia (MaRVeL Study)

开始日期2023-07-05

申办/合作机构

The University of Sydney

100 项与木聚硫钠相关的临床结果

登录后查看更多信息

100 项与木聚硫钠相关的转化医学

登录后查看更多信息

100 项与木聚硫钠相关的专利（医药）

登录后查看更多信息

1,236

项与木聚硫钠相关的文献（医药）

2025-12-01·Current Urology Reports

Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature

Review

作者: Sawyer, Kathryn ; Zheng, Yu ; Gupta, Priyanka ; Aqeel, Jawad

PURPOSE OF REVIEW:

The management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis.

RECENT FINDINGS:

Several novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.

2025-10-01·FOOD CHEMISTRY

In vitro simulated digestion and fermentation characteristics of pumpkin polysaccharides and their effects on the human gut microbiota

Article

作者: Cao, Hongyuan ; Lin, Changbin ; Ge, Lihong ; Wang, Chun ; Xia, Chen ; Miao, Yuzhi ; Li, Kejuan ; Li, Qi ; Li, Jiajun ; Zhu, Yuanting

Although pumpkin polysaccharides have numerous health benefits, limited studies have investigated the impact of pumpkin polysaccharide digestion and fermentation characteristics on its biological activity. Herein, pumpkin polysaccharides (PPs) were subjected to simulated saliva-gastric-small intestinal digestion, followed by in vitro fermentation using healthy human faecal microbiota. Results indicate that PPs, acidic heteropolysaccharide with a molecular weight of 2.93 × 10² kDa, mainly composed glucose and D-galacturonic acid and remained stable under simulated salivary and gastric conditions; however, they slightly degraded during intestinal digestion. During in vitro faecal fermentation, PPs stimulated the production of short-chain fatty acids, particularly acetic acid, which lowered pH, promoted the abundance of beneficial bacteria such as Lactobacillus, and inhibited harmful bacteria such as Escherichia-Shigella and Phascolarctobacterium. PICRUSt analysis suggested that the gut microbiota regulation of PPs was linked to metabolic pathways and amino acid biosynthesis, indicating the potential prebiotic properties and health benefits of PPs.

2025-09-01·Ophthalmology Retina

Risk and Dose–Response Relationship for Pentosan Polysulfate Sodium Maculopathy

Review

作者: Lim, Kate ; Tao, Brendan K ; Gupta, Rudra Rishi ; Dhivagaran, Thanansayan ; Butt, Fahad ; Mishra, Amit ; Sawires, Korolos

TOPIC:

To determine the pooled relative risk (RR) of pentosan polysulfate sodium maculopathy (PPSM) in patients using pentosan polysulfate sodium (PPS) and model the dose-response relationship of this association from existing literature.

CLINICAL RELEVANCE:

Pentosan polysulfate sodium maculopathy is an acquired, progressive retinal pigmentary disease associated with oral PPS use. Although several observational studies suggest a dose-response relationship of this association, to date, there remains no literature-pooled synthesis on the risk of PPSM across strata of cumulative dose.

METHODS:

Systematic review and meta-analysis (CRD42024623179). Medline, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to September 15, 2024. We included studies reporting the incidence of PPS-associated maculopathy and including cumulative PPS dose information. Two independent reviewers completed study screening, data extraction, and risk of bias (ROB) assessment using the ROB in nonrandomized studies of exposures tool, and a third reviewer was consulted to resolve conflicts. The primary outcome was the RR of PPSM among patients exposed to PPS compared with nonexposed individuals, stratified by cumulative PPS dose.

RESULTS:

We included 5 studies encompassing 141 785 patients and 6432 PPSM cases. The linear dose-response regression model estimated a 0.1% increase in RR of maculopathy per g increase in cumulative PPS dose (log-transformed RR = 0.00101; 95% confidence interval, 0.0005-0.0015; P < 0.0001). Patients with cumulative doses ≥2000 g exhibited an RR of 7.39 (95% confidence interval, 4.17-13.10), while those with a dose between 1 and 500 g had an RR of 1.65 (95% confidence interval, 1.12-2.43) compared with nonexposed individuals. Subgroup analysis excluding high-risk studies demonstrated consistent findings, with reduced heterogeneity (I² = 63.7%).

CONCLUSION:

Moderate certainty evidence supports a dose-dependent relationship between PPS exposure and PPSM risk, whereas higher cumulative doses significantly increase maculopathy risk. This result supports that patients should be tapered to an effective minimal dose and that they should be subject to interval maculopathy screening, especially for patients with greater cumulative dose. Future research should incorporate patient-level data to better control for potential confounding.

FINANCIAL DISCLOSURE(S):

The authors have no proprietary or commercial interest in any materials discussed in this article.

项与木聚硫钠相关的新闻（医药）

2025-09-16

·PRNewswire

Parker Waichman LLP Files Lawsuit on Behalf of Baltimore Resident Alleging Irreversible Eye Condition After Taking Ozempic

PORT WASHINGTON, N.Y., Sept. 16, 2025 /PRNewswire/ -- National law firm Parker Waichman LLP has filed another lawsuit in New Jersey state court on behalf of an individual who developed non-arteritic anterior ischemic optic neuropathy (NAION) after taking Ozempic, a widely prescribed GLP-1 receptor agonist. The latest case, Christensen v. Novo Nordisk Inc., Docket No. MID-L-0056489-25, was filed September 8, 2025, on behalf of a Baltimore, Maryland resident. This filing adds to a growing number of lawsuits brought by Parker Waichman on behalf of patients who suffered irreversible eye injuries, including partial or complete vision loss, after being prescribed Ozempic or Wegovy. Serious Risks Tied to Popular Diabetes and Weight Loss Drugs Originally developed to treat Type 2 diabetes, semaglutide (marketed as Ozempic and Wegovy) has skyrocketed in use for weight loss. However, recent research has linked the drug to NAION, a permanent condition that cuts off blood flow to the optic nerve and can result in blindness. A 2025 study in JAMA Ophthalmology reported multiple cases of optic nerve disorders among GLP-1 users, most with NAION-like symptoms. Separately, researchers at Harvard's Mass Eye and Ear Institute found that diabetic patients using semaglutide faced a fourfold increased risk of NAION, while non-diabetic users taking it for weight loss had a sevenfold increased risk. Despite mounting evidence, Novo Nordisk has not issued adequate warnings about the risk of blindness associated with these drugs. Parker Waichman LLP Advocates for Victims Nationwide "NAION is a devastating, permanent eye injury," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. "Multiple studies from respected institutions confirm a statistically significant link between semaglutide and NAION. Yet, Novo Nordisk continues to deny reality by failing to warn the public and medical professionals. They must be held accountable." Parker Waichman LLP is actively reviewing cases nationwide for individuals who have suffered sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy. Potential compensation may include coverage for medical costs, lost income, pain and suffering, and other damages. Free Case Evaluations Available Individuals who experienced serious eye injuries after taking Ozempic or Wegovy are encouraged to contact Parker Waichman LLP for a free, no-obligation case review. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit . About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm committed to protecting victims of defective drugs, dangerous products, accidents, and corporate negligence. The firm has extensive experience representing clients in pharmaceutical eye injury cases, including In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Products Liability Litigation. Parker Waichman has secured billions of dollars in verdicts and settlements on behalf of injured clients. Media Contact: Parker Waichman LLP Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权

2025-09-05

·药学进展

行业动态 | 首个“中国籍”地舒单抗成功出海，复宏汉霖与Organon共同宣布BILDYOS®和BILPREVDA®在美获批上市

“ 点击蓝字关注我们首个“中国籍”地舒单抗成功出海，复宏汉霖与Organon共同宣布BILDYOS®和BILPREVDA®在美获批上市 PPS 中国上海 & 美国新泽西州泽西市，2025年9月2日 —— 复宏汉霖（2696.HK）与Organon（纽交所代码：OGN）今日共同宣布，美国食品药品监督管理局（FDA）已批准地舒单抗注射液（60mg/mL）BILDYOS®（denosumab-nxxp）和地舒单抗注射液（120mg/1.7mL）BILPREVDA®（denosumab-nxxp）的上市申请。两款产品分别为PROLIA®（denosumab）和XGEVA®（denosumab）的生物类似药，此次获批覆盖原研产品在美国已获批的所有适应症。 Organon生物类似药和普药业务美国商业主管 Jon Martin 表示：“BILDYOS和BILPREVDA 的FDA成功获批标志着我们朝提升关键骨骼护理治疗可及性迈出了重要一步。数百万美国人，都需要这些治疗，尤其是日益增长的老龄化人口。我们开发这些生物类似药的目标是提高多个治疗领域的可及性和可负担性，包括对女性影响很大的骨质疏松症。此次获批彰显了 Organon 坚定不移地致力于让患者获得优质且高品质、可负担的治疗，同时致力于为骨骼健康护理创造更可持续的未来。” BILDYOS 是一种RANK配体（RANKL）抑制剂，适用于以下人群：治疗绝经后妇女的高风险骨质疏松症；增加骨量治疗及预防骨折高风险的糖皮质激素引起的女性与男性骨质疏松症；接受雄激素剥夺治疗（ADT）的骨折高风险的非转移性前列腺癌男性患者的增加骨量治疗；以及接受芳香酶抑制剂辅助治疗的非转移性乳腺癌女性患者的增加骨量治疗。完整适应症见下文。使用 BILDYOS 治疗的晚期肾病患者存在更高的严重低钙血症风险。已有报告显示，地舒单抗类产品可导致严重低钙血症，并引发住院、危及生命的事件，甚至死亡病例。慢性肾脏病-矿物质与骨异常（CKD-MBD）的存在会显著增加低钙血症风险。在为晚期慢性肾病患者启动 BILDYOS 治疗之前，应评估其是否存在 CKD-MBD。这类患者的 BILDYOS 治疗应在具备 CKD-MBD 诊断和管理经验的医疗专业人员监督下进行。更多安全性信息见下文。 BILPREVDA 是一种 RANK 配体（RANKL）抑制剂，适用于多发性骨髓瘤患者和实体瘤骨转移患者的骨相关事件，也适用于骨巨细胞瘤患者以及恶性肿瘤相关高钙血症的治疗。完整适应症见下文。使用包括 BILPREVDA 在内的地舒单抗类产品可能引发过敏反应，包括过敏性休克。一旦发生临床显著的过敏反应，应立即并永久停药。地舒单抗类产品可导致严重的有症状的低钙血症，且已有死亡病例报告。在开始 BILPREVDA 治疗前应先纠正原先存在的低钙血症，整个 BILPREVDA 治疗期间应监测血钙水平，尤其是开始治疗的最初数周内，同时应为所有患者补充足量的钙和维生素D。接受地舒单抗治疗的患者中已有颌骨坏死（ONJ）事件的报告，开始 BILPREVDA 治疗前应进行口腔检查，并在治疗过程中监测相关症状，避免在治疗期间进行侵入性牙科手术。若患者出现大腿或腹股沟区疼痛，应接受评价以排除股骨骨折。当停止 BILPREVDA 治疗时，应评估患者发生椎体骨折的风险。孕妇使用 BILPREVDA 可能会对胎儿造成损害，应当告知具备生育力的女性暴露于 BILPREVDA 可能会导致胎儿损害，并建议采取有效避孕措施。更多安全性信息见下文。复宏汉霖执行董事兼首席执行官朱俊博士表示：“BILDYOS 和 BILPREVDA 获得美国 FDA 批准，标志着复宏汉霖又一批自主研发、自主生产的生物类似药取得美国监管认可，也体现了我们对科学卓越和产品质量的承诺。我们很荣幸能够通过与 Organon 的合作，继续扩大优质生物药的可及性，为更多美国患者提供在疗效和安全性上与原研药同等的生物类似药治疗选择。” BILDYOS 和 BILPREVDA 的获批是基于一整套全面数据的审查，其中包括结构与功能分析数据、临床药代动力学数据，以及一项临床对比研究。研究表明，BILDYOS 和BILPREVDA 在安全性、纯度和效力方面与原研药 PROLIA 和 XGEVA 高度相似，且无临床意义上的差异。 2022年，复宏汉霖与 Organon 签订许可与供应协议，授予 Organon 对包括BILDYOS 和 BILPREVDA 在内的多个生物类似药在除中国以外的全球区域的独家商业化权益。复宏汉霖首席商务发展官兼高级副总裁曹平表示：“此次美国获批彰显了复宏汉霖与Organon 之间强有力的合作，旨在扩大患者获得优质且可能更实惠的生物类似药的渠道。我们正携手合作，扩大重要治疗方案的可及性，更好地满足美国患者和医疗机构的需求。” BILDYOS和BILPREVDA的获批，进一步充实了 Organon 在美国的生物类似药产品组合。该组合已深耕逾八年，覆盖五大主要治疗领域。这一获批里程碑体现了Organon 始终秉持的承诺——专注于提升兼具质量和患者成本效益治疗方案的可及性，并通过可持续、以患者为中心的方式推进女性健康。关于复宏汉霖复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已有6款产品在中国获批上市，6款产品在国际获批上市，5个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖约50个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。截至目前，公司已获批上市产品包括全球首个获批一线治疗小细胞肺癌的抗PD-1单抗汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、国内首个生物类似药汉利康®（利妥昔单抗）、以及地舒单抗生物类似药Bildyos®和Bilprevda®。公司亦同步就19个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。关于Organon Organon（纽约证券交易所代码：OGN）是一家全球化医疗健康公司，使命是提供有深远影响的药物与解决方案，让人们的每一天更健康。公司专注于解决独特，重点，或以不同方式影响女性的健康需求，提供超过70种女性健康与常规药物的产品组合，其中包括生物类似药，同时在全球140多个市场扩大基本治疗手段的可及性。文章来源：复宏汉霖美编排版：方正文章审核：周碧远方正罗琪【免责声明】以上内容来源于互联网，不代表本平台立场或观点；如有侵犯作者著作权，请及时与我们联系（Tel：025-83271227，或直接在微信平台留言），我们将及时更正或删除。《药学进展》杂志由教育部主管、中国药科大学主办，中国科技核心期刊（中国科技论文统计源期刊）。刊物以反映药学科研领域的新方法、新成果、新进展、新趋势为宗旨，以综述、评述、行业发展报告为特色，以药学学科进展、技术进展、新药研发各环节技术信息为重点，是一本专注于医药科技前沿与产业动态的专业媒体。《药学进展》注重内容策划、加强组稿约稿、深度挖掘、分析药学信息资源、在药学学科进展、科研思路方法、靶点机制探讨、新药研发报告、临床用药分析、国际医药前沿等方面初具特色；特别是医药信息内容以科学前沿与国家战略需求相合，更加突出前瞻性、权威性、时效性、新颖性、系统性、实战性。根据最新统计数据，刊物篇均下载率连续三年蝉联我国医药期刊榜首，复合影响因子1.216，具有较高的影响力。《药学进展》编委会由国家重大专项化学药总师陈凯先院士担任主编，编委由新药研发技术链政府监管部门、高校科研院所、制药企业、临床医院、CRO、金融资本及知识产权相关机构近两百位极具影响力的专家组成。联系《药学进展》↓↓↓ 编辑部官网：pps.cpu.edu.cn；邮箱：yxjz@163.com；电话：025-83271227。欢迎投稿、订阅！往期推荐聚焦“兴药为民·2023生物医药创新融合发展大会”“兴药为民·2023生物医药创新融合发展大会”盛大启幕！院士专家齐聚杭城，绘就生物医药前沿赛道新蓝图“兴药强刊”青年学者论坛暨《药学进展》第二届青年编委会议成功召开“兴药为民·2023生物医药创新融合发展大会”路演专场圆满收官！校企合作新旅程已启航我知道你在看哟

上市批准生物类似药

2025-08-20

·PRNewswire

Parker Waichman LLP Files Lawsuit on behalf of Long Island Resident Alleging Vision Loss and Development of Irreversible Eye Condition, NAION, after taking Ozempic

Parker Waichman, a national law firm, has filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo Nordisk's Ozempic or Wegovy. The NAION/Ozempic lawsuits were recently featured in Newsday PORT WASHINGTON, N.Y., Aug. 20, 2025 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits in New Jersey state court on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. Most recently, on August 18, 2025, the Firm filed a lawsuit on behalf of a Long Island, New York resident who developed NAION after taking Ozempic. See Barzyz v. Novo Nordisk Inc., Docket No: MID-L-005991-25. The lawsuit, along with the NAION/Ozempic litigation, was recently covered by Newsday. See Injectable weight loss drugs linked to rare vision loss - Newsday. Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fights for Victims Nationwide "NAION is a devastating, and permanent, eye injury diagnosis. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable." said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Prod. Liab. Litig. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Parker Waichman LLP Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权

100 项与木聚硫钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05428	木聚硫钠	C05BA04 G04BX15	DBSALT000991

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
间质性膀胱炎	美国	Janssen Pharmaceuticals, Inc.	1996-09-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	欧盟	Paradigm Biopharmaceuticals Ltd.	2022-03-18
骨关节炎	临床3期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
膀胱炎	临床3期	中国台湾	泰宗生物科技股份有限公司	2020-10-14
泌尿道感染	临床3期	中国台湾	泰宗生物科技股份有限公司	2020-10-14
黏多糖贮积症I型	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
黏多糖贮积症VI型	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
过敏性鼻炎	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
罗斯河热	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
慢性前列腺炎	临床2期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2005-10-12
慢性前列腺炎	临床2期	-	ALZA Corp.	2005-10-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


2021 ARVO Annual Meeting (ARVO2021)	N/A	黄斑变性	-	Pentosan Polysulfate	餘獵餘願壓獵範膚窪鑰(齋憲憲網艱壓築鏇遞築) = 艱顧餘觸窪範齋範網簾簾獵壓鹹鏇築製窪糧網 (襯獵鏇積壓積壓醖積鏇, 238 ~ 290) 更多	不佳	2021-06-01
NCT02930005 (CTgov)	临床2期	躁郁症 \| 躁郁症1型 \| 分裂情感性障碍 ... 更多	8	Meclofenamic acid (Meclofenamic Acid)	壓壓構網壓夢顧醖糧憲 = 壓衊蓋鑰衊構鹹願願構積顧觸艱糧鑰鹹膚窪鹽 (蓋壓範憲鑰構製鹹願襯, 築鏇蓋餘願廠網鬱淵觸 ~ 糧鹽鑰襯顧鹹膚積艱選) 更多	-	2019-03-26
NCT02930005 (CTgov)	临床2期	躁郁症 \| 躁郁症1型 \| 分裂情感性障碍 ... 更多	8	Pentosan polysulfate sodium (Pentosan Polysulfate Sodium)	壓壓構網壓夢顧醖糧憲 = 憲衊繭膚鏇觸選淵範醖積顧觸艱糧鑰鹹膚窪鹽 (蓋壓範憲鑰構製鹹願襯, 餘壓淵齋艱齋衊積糧衊 ~ 衊獵鬱齋壓遞鏇壓獵積) 更多	-	2019-03-26
NCT00086684 (CTgov)	临床4期	间质性膀胱炎	369	Placebo	醖構餘網網衊襯餘繭繭 = 糧糧觸製築淵糧製構鹹鏇鏇網衊鑰窪鏇繭醖築 (窪襯觸淵網餘範繭網衊, 獵遞醖願襯獵範餘廠衊 ~ 壓蓋醖鏇網顧遞襯簾觸) 更多	-	2012-07-06